Document:

Form of Non-Executive Employee Restricted Stock Unit Grant Notice

 Exhibit 10.48 
 KOSAN BIOSCIENCES INCORPORATED 
 RESTRICTED STOCK UNIT GRANT NOTICE 
 (2006
EQUITY INCENTIVE PLAN) 
 Kosan Biosciences Incorporated (the “Company”), pursuant
to Section 7(b) of the Company’s 2006 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award covering the number of restricted stock units (the “RSUs”)
set forth below (the “Award”). This Award shall be evidenced by a Restricted Stock Unit Award Agreement (the “Award Agreement”). This Award is subject to all of the terms and conditions as set forth
herein and in the applicable Award Agreement and the Plan, each of which are attached hereto and incorporated herein in their entirety. 
  

			
	 Participant:
	 	 
	 Date of Grant:
	 	 
	 Vesting Commencement Date:
	 	 
	 Number of RSUs:
	 	 
	 Payment for Common Stock:
	 	Participant’s services to the Company

 Vesting Schedule: The RSUs vest in two components: a performance-based component and a time-based
component. 
  

			
	Performance-Based Vesting:	  	 One-third of the total number of RSUs set forth above shall vest if:
  

•        the Company has met all of its 2008 Corporate Goals, as determined by
the Compensation Committee of the Board (the “Committee”) in its sole and absolute discretion, provided that if the Committee determines that a percentage less than 100% of the Company’s 2008 Corporate Goals has been met (which such
percentage shall be determined by the Committee in its sole and absolute discretion), then the number of RSUs that shall vest under this paragraph shall equal such percentage multiplied by one-third of the total number of RSUs set forth above, and

  
 •        you remain an Employee through the date that the Committee makes the determination set forth above.

	Time-Based Vesting:	  	If you remain an Employee through December 31, 2009, one-third of the total number of RSUs set forth above shall vest. If you remain an Employee through December 31, 2010, one-third of the total
number of RSUs set forth above shall vest.

 Delivery Schedule: Delivery of one share of Common Stock for each RSU which vests shall occur on the
applicable vesting date, provided that delivery may be delayed as provided in Section 3 of the Award Agreement. 
  

						
	Special Tax Withholding Right:	  	x	 	  	You may direct the Company (i) to withhold, from shares otherwise issuable upon vesting of the Award, a portion of those shares with an aggregate fair market value (measured as of the delivery
date) equal to the amount of the applicable withholding taxes, and (ii) to make a cash payment equal to such fair market value directly to the appropriate taxing authorities, as provided in Section 10 of the Award Agreement.
			
		  	 ̈	 	  	None

  

 1. 

 Additional Terms/Acknowledgements: Participant acknowledges receipt of, and understands and agrees to, this Grant
Notice, the Award Agreement and the Plan. Participant further acknowledges that as of the Date of Grant, this Grant Notice, the Award Agreement and the Plan set forth the entire understanding between Participant and the Company regarding the award
of the RSUs and the underlying Common Stock and supersede all prior oral and written agreements on that subject with the exception of (i) Stock Awards previously granted and delivered to Participant under the Plan, and (ii) the following
agreements only: 
  

									
	 OTHER AGREEMENTS:
	 	 
			
	KOSAN BIOSCIENCES INCORPORATED	 		 	PARTICIPANT
					
	By:	 	 	 		 		 	 
		 	Signature	 		 		 	Signature
					
	Title:	 	 	 		 	Date:	 	 
					
	Date:	 	 	 		 		 	

 ATTACHMENTS: Award Agreement, and Plan 
  

 2. 

 KOSAN BIOSCIENCES INCORPORATED 
 2006 EQUITY INCENTIVE PLAN 
 RESTRICTED STOCK UNIT AWARD AGREEMENT 
 Pursuant to the Restricted Stock Unit Grant Notice (“Grant Notice”) and this Restricted Stock Unit Award Agreement (“Agreement”), Kosan Biosciences Incorporated (the
“Company”) has awarded you a Restricted Stock Unit Award pursuant to the Company’s 2006 Equity Incentive Plan (the “Plan”) for the number of restricted stock units (“RSUs”)
as indicated in the Grant Notice (collectively, the “Award”). Defined terms not explicitly defined in this Agreement but defined in the Plan shall have the same definitions as in the Plan. Subject to adjustment and the terms
and conditions as provided herein and in the Plan, each RSU shall represent the right to receive one (1) share of Common Stock. 
 The
details of your Award, in addition to those set forth in the Grant Notice, are as follows. 
 1. NUMBER
OF RSUS AND SHARES OF COMMON STOCK. 
 (a) The number of RSUs subject to your Award and the number of shares of Common Stock deliverable with respect to such RSUs may be adjusted from time to time for Capitalization Adjustments as described in
Section 9(a) of the Plan. You shall receive no benefit or adjustment to your Award with respect to any cash dividend or other distribution that does not result from a Capitalization Adjustment as described in Section 9(a) of the Plan;
provided, however, that this sentence shall not apply with respect to any shares of Common Stock that are delivered to you in connection with your Award after such shares have been delivered to you. 
 (b) Any additional RSUs, shares of Common Stock, cash or other property that becomes subject to the Award pursuant to this
Section 1 shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other RSUs and Common Stock covered by your Award.

 (c) Notwithstanding the provisions of this Section 1, no fractional RSUs or rights for fractional shares of
Common Stock shall be created pursuant to this Section 1. The Board shall, in its discretion, determine an equivalent benefit for any fractional RSUs or fractional shares that might be created by the adjustments referred to in this
Section 1. 
 2. VESTING. Except as provided in Section 11, the RSUs
shall vest, if at all, as provided in the Vesting Schedule set forth in your Grant Notice, provided that vesting shall cease upon the termination of your service as an Employee that constitutes Continuous Service. If an RSU with respect to one share
of Common Stock would otherwise vest in fractional amounts pursuant to the Vesting Schedule set forth in your Grant Notice, such RSU shall instead vest, if at all, on the final vesting date under such Vesting Schedule. 
  

 1. 

 3. DELIVERY OF SHARES OF
COMMON STOCK. 
 (a) Subject to the provisions of this Award Agreement and the Plan,
in the event one or more RSUs vests, the Company shall deliver to you one share of Common Stock for each RSU that vests on the applicable vesting date. However, if a scheduled delivery date falls on a date that is not a business day, such delivery
date shall instead fall on the next following business day. 
 (b) Notwithstanding the foregoing, in the event that you
are subject to the stock trading restrictions contained in the Company’s Amended and Restated Policy & Procedures Regarding Prevention of Insider Trading and Protection of Confidential Information (or any successor policy) and
any shares covered by your Award are scheduled to be delivered on a day (the “Original Delivery Date”) that does not occur during an open “window period” applicable to you, as determined by the Company in accordance
with such policy, then such shares shall not be delivered on such Original Delivery Date and shall instead be delivered on the first business day of the next occurring open “window period” but in no event later than the later of:
(i) December 31st of the calendar year of the Original Delivery Date, or (ii) the fifteenth (15th) day of the third calendar month following the Original Delivery Date. The form of such delivery (e.g., a stock certificate
or electronic entry evidencing such shares) shall be determined by the Company. 
 4. PAYMENT BY
YOU. This Award was granted in consideration of your services for the Company. Subject to Section 10 below, except as otherwise provided in the Grant Notice, you will not be required to make any
payment to the Company (other than your past and future services for the Company) with respect to your receipt of the Award, vesting of the RSUs, or the delivery of the shares of Common Stock underlying the RSUs. 
 5. SECURITIES LAW COMPLIANCE. You may not be issued any Common
Stock under your Award unless either (i) the shares of Common Stock are then registered under the Securities Act, or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities
Act. Your Award must also comply with other applicable laws and regulations governing the Award, and you shall not receive such Common Stock if the Company determines that such receipt would not be in material compliance with such laws and
regulations. 
 6. RESTRICTIVE LEGENDS. The Common Stock issued under your Award shall be
endorsed with appropriate legends, if any, determined by the Company. 
 7. TRANSFER
RESTRICTIONS. Prior to the time that shares of Common Stock have been delivered to you, you may not transfer, pledge, sell or otherwise dispose of the shares in respect of your Award. For example, you may not use shares that may
be issued in respect of your RSUs as security for a loan, nor may you transfer, pledge, sell or otherwise dispose of such shares. This restriction on transfer will lapse upon delivery to you of shares in respect of your vested RSUs. Your Award is
not transferable, except by will or by the laws of descent and distribution. Notwithstanding the foregoing, by delivering written notice to the Company, in a form satisfactory to the Company, you may designate a third party who, in the event of your
death, shall thereafter be entitled to receive any distribution of Common Stock to which you were entitled at the time of your death pursuant to this Agreement. 
  

 2. 

 8. AWARD NOT A SERVICE
CONTRACT. Your Award is not an employment or service contract, and nothing in your Award shall be deemed to create in any way whatsoever any obligation on your part to continue in the service of the
Company or any Affiliate, or on the part of the Company or any Affiliate to continue such service. In addition, nothing in your Award shall obligate the Company or any Affiliate, their respective stockholders, boards of directors or employees to
continue any relationship that you might have as an Employee or Consultant of the Company or any Affiliate. 
 9.
UNSECURED OBLIGATION. Your Award is unfunded, and even as to any RSUs that vest, you shall be considered an unsecured creditor of the Company with respect to the Company’s
obligation, if any, to issue Common Stock pursuant to this Agreement. You shall not have voting or any other rights as a stockholder of the Company with respect to the Common Stock acquired pursuant to this Agreement until such Common Stock is
issued to you pursuant to Section 3 of this Agreement. Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company with respect to the Common Stock so issued. Nothing contained in this Agreement, and no
action taken pursuant to its provisions, shall create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person. 
 10. WITHHOLDING OBLIGATIONS. 
 (a) On or before the time you receive a distribution of Common Stock pursuant to your Award, or at any time thereafter as requested
by the Company, you hereby authorize any required withholding from the Common Stock issuable to you and/or otherwise agree to make adequate provision in cash for any sums required to satisfy the federal, state, local and foreign tax withholding
obligations of the Company or any Affiliate which arise in connection with your Award (the “Withholding Taxes”). If specified in your Grant Notice, you may direct the Company to withhold shares of Common Stock with a Fair
Market Value (measured as of the date shares of Common Stock are delivered pursuant to Section 3) equal to the amount of such Withholding Taxes; provided, however, that the number of such shares of Common Stock so withheld shall not
exceed the amount necessary to satisfy the Company’s required tax withholding obligations using the minimum statutory withholding rates for federal, state, local and foreign tax purposes, including payroll taxes, that are applicable to
supplemental taxable income. 
 (b) Unless the tax withholding obligations of the Company and/or any Affiliate are
satisfied, the Company shall have no obligation to deliver to you any Common Stock. 
  

 3. 

 11. CHANGE IN CONTROL. 
 (a) With respect to that portion of the RSUs subject to your Award that is subject to performance-based vesting under the Vesting
Schedule set forth in your Grant Notice, such portion will vest in full upon the effective date of a Change in Control, provided you are an Employee in Continuous Service on such date. With respect to that portion of the RSUs subject to your Award
that is subject to time-based vesting under the Vesting Schedule set forth in your Grant Notice, such portion will vest in full if your Continuous Service as an Employee terminates either within twelve (12) months following or one
(1) month prior to the effective date of a Change in Control due to an Involuntary Termination Without Cause. 
 (b) For purposes of this Agreement, “Involuntary Termination Without Cause” means the involuntary termination of your Continuous Service for reasons other than death, Disability, or Cause. For this purpose,
“Cause” means that, in the reasonable determination of the Company, you have (i) committed an intentional act or acted with gross negligence that has materially injured the business of the Company; (ii) intentionally refused or
failed to follow lawful and reasonable directions of the Board or the appropriate individual to whom you report; (iii) willfully and habitually neglected your duties for the Company; or (iv) been convicted of a felony involving moral
turpitude that is likely to inflict or has inflicted material injury on the business of the Company. Notwithstanding the foregoing, Cause shall not exist based on conduct described in clause (ii) or (iii) unless the conduct described in
such clause has not been cured within fifteen (15) days following your receipt of written notice from the Company specifying the particulars of the conduct constituting Cause. Any determination by the Company that your Continuous Service was
terminated by reason of dismissal without Cause for the purposes of this Agreement shall have no effect upon any determination of the rights or obligations of you or the Company for any other purpose. 
 12. PARACHUTE PAYMENTS. 
 (a) If any payment or benefit you would receive in connection with a Change in Control from the Company or otherwise
(“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the
Code (the “Excise Tax”), then the Company shall cause to be determined, before any amounts of the Payment are paid to you, which of the following two alternative forms of payment would maximize your after-tax proceeds:
(i) payment in full of the entire amount of the Payment (a “Full Payment”), or (ii) payment of only a part of the Payment so that you receive the largest payment possible without the imposition of the Excise Tax (a
“Reduced Payment”), whichever amount results in your receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. For purposes
of determining whether to make a Full Payment or a Reduced Payment, the Company shall cause to be taken into account all applicable federal, state and local income and employment taxes and the Excise Tax (all computed at the highest applicable
marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes). 
 (b) If a Reduced Payment is made, (i) the Payment shall be paid only to the extent permitted under the Reduced Payment alternative, and you shall have no rights to any additional payments and/or benefits
constituting the Payment, and (ii) reduction in payments and/or benefits shall occur in the following order unless you elect in writing a different order (provided, however, that such election shall be subject to Company approval if made on or
after the date on which the event that triggers the Payment occurs): (1) reduction of cash payments; (2) cancellation of accelerated vesting of equity awards other than stock options; (3) cancellation 

  

 4. 

 
of accelerated vesting of stock options; and (4) reduction of other benefits paid to you. In the event that acceleration of compensation from your
equity awards is to be reduced, such acceleration of vesting shall be canceled in the reverse order of the date of grant (i.e., earliest granted Stock Award cancelled last) unless you elect in writing a different order for cancellation. 

(c) The accounting firm engaged by the Company for general tax purposes as of the day prior to the effective date of the Change
in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally
recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. 
 (d) The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed
supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which your right to a Payment is triggered (if requested at that time by you or the Company) or such other time as requested by you or the
Company. If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish you and the Company with an opinion reasonably acceptable to you that
no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon you and the Company. 
 13. NOTICES. Any notices required to be given or delivered to the Company under the terms of
this Award shall be in writing and addressed to the Company at its principal corporate offices. Any notice required to be given or delivered to you shall be in writing and addressed to your address as on file with the Company at the time notice is
given. All notices shall be deemed effective upon personal delivery or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified. 
 14. HEADINGS. The headings of the Sections in this Agreement are inserted for convenience only and shall not be deemed to constitute a part of this Agreement or to affect the meaning of
this Agreement. 
 15. AMENDMENT. This Agreement may be amended only by a writing executed by the Company and
you which specifically states that it is amending this Agreement. Notwithstanding the foregoing, this Agreement may be amended solely by the Company by a writing which specifically states that it is amending this Agreement, so long as a copy of such
amendment is delivered to you, and provided that no such amendment adversely affecting your rights hereunder may be made without your written consent. Without limiting the foregoing, the Company reserves the right to change, by written notice to
you, the provisions of this Agreement in any way it may deem necessary or advisable to carry out the purpose of the grant as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial decision,
provided that any such change shall be applicable only to rights relating to that portion of the Award that has not been delivered to you in Common Stock pursuant to Section 3. 
  

 5. 

 16. MISCELLANEOUS. 
 (a) The rights and obligations of the Company under your Award shall be transferable by the Company to any one or more persons or
entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by the Company’s successors and assigns. 
 (b) You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your Award. 
 (c) You acknowledge and agree that you have reviewed your Award in its entirety, have had an opportunity to obtain the advice of
counsel prior to executing and accepting your Award and fully understand all provisions of your Award. 
 (d) This
Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required. 
 (e) All obligations of the Company under the Plan and this Agreement shall be binding on any successor to the Company, whether the
existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company. 
 17. GOVERNING PLAN DOCUMENT. Your Award is subject to all the
provisions of the Plan, the provisions of which are hereby made a part of your Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan. In
the event of any conflict between the provisions of your Award and those of the Plan, the provisions of the Plan shall control; provided, however, that Section 3 of this Agreement shall govern the timing of any distribution of Common
Stock under your Award. The Company shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation, and application of the Plan as are consistent therewith and to interpret or revoke any
such rules. All actions taken and all interpretations and determinations made by the Board shall be final and binding upon you, the Company, and all other interested persons. No member of the Board shall be personally liable for any action,
determination, or interpretation made in good faith with respect to the Plan or this Agreement. 
 18. EFFECT
ON OTHER EMPLOYEE BENEFIT PLANS. The value of the Award subject to this Agreement shall not be included as compensation, earnings, salaries, or other similar terms used
when calculating benefits under any employee benefit plan (other than the Plan) sponsored by the Company or any Affiliate except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any
or all of the employee benefit plans of the Company or any Affiliate. 
 19. CHOICE OF
LAW. The interpretation, performance and enforcement of this Agreement shall be governed by the law of the state of California without regard to such state’s conflicts of laws rules. 
  

 6. 

 20. SEVERABILITY. If all or any part of this Agreement or the Plan is
declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Agreement (or part
of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.

 21. OTHER DOCUMENTS. You hereby acknowledge receipt or the right to receive a document
providing the information required by Rule 428(b)(1) promulgated under the Securities Act (which includes the prospectus for the Plan). In addition, you acknowledge receipt of the Company’s Amended and Restated Policy & Procedures
Regarding Prevention of Insider Trading and Protection of Confidential Information. 
 * * * * * 
 This Restricted Stock Unit Award Agreement shall be deemed to be signed by the Company and you upon the signing by you of the Restricted Stock Unit Grant
Notice to which it is attached. 
  

 7.Severance Benefits and Consulting Agreement - Robert L. De Jager, M.D., F.A.C.P.

 Exhibit 10.49 
 

 
  
 August 1, 2007

 VIA HAND DELIVERY 
 Robert De Jager, M.D. 
  

	Re:	Transition Terms 

 Dear Robert: 
 This letter confirms our agreement regarding your transition from Kosan Biosciences Incorporated (the “Company”). As agreed, your employment with the Company
will terminate, effective, August 8, 2007 (“Termination Date”). 
 Severance Benefits and Consulting Agreement 
 If you sign and return this letter, and then on or after the Termination Date, you sign, date and return the Release Agreement enclosed herewith, and allow it to become
effective, you will receive the following as your sole severance benefits (the “Severance Benefits”): 
  

	 	•	 	 Severance pay equal to four (4) months of your final base salary, subject to required payroll deductions and withholdings (“Severance Payment”),

  

	 	•	 	 If you timely elect continued group health insurance coverage pursuant to federal COBRA law (discussed further below), the Company will pay your COBRA premiums
sufficient to continue your group health insurance coverage (including your wife’s continued coverage, if elected) at the same level of coverage in effect as of the Termination Date, through the end of November 2007, and

  

	 	•	 	 The Company will not expect repayment of your $50,000 sign on bonus, despite the termination of your employment within the first year. Of course, you understand and
agree that you will be responsible for covering any expenses incurred by you following your Termination Date, including but not limited to expenses associated with your temporary housing in the Bay Area or your relocation to San Diego or any other
location. 

 As a condition of your receipt of the Severance Benefits, you agree not to inform or confirm to others that you have received
any severance benefits from the Company, with the exceptions of your immediate family, or your attorneys, accountants, auditors, tax preparers, and financial advisors. By way of example, but not limitation, you must not disclose the Severance
Benefits to other Company employees or consultants. 
 In addition, if you meet the conditions for eligibility for the Severance Benefits as enumerated in
this letter, the Company and you agree to enter into the Consulting Agreement enclosed with this letter, which establishes a consulting relationship between you and the Company effective on the Termination Date and continuing through no later than
November 8, 2007 (“Consulting Agreement”). 

 Page 2 of 3 
  

 Severance Payment 
 The lump sum Severance Payment will be mailed to you within ten (10) business days after the Effective Date of the Release Agreement (as defined in the Release Agreement). 
 Final Pay, Expense Reimbursements and Benefits 
 Enclosed is your final pay. This amount includes your accrued salary
through the Termination Date, and payment for your accrued but unused vacation through the Termination Date, less applicable taxes and required deductions. 
 If you have any outstanding business expenses, you must complete and submit a properly documented business expense reimbursement form as soon as possible and no later than within thirty (30) days after the Termination Date. The Company
will, pursuant to its regular business practice, reimburse you for legitimate and documented business expenses incurred through the Termination Date, if any. 
 Your health care coverage will terminate on August 31, 2007, and, to the extent provided by the federal COBRA law or, if applicable, state insurance laws (collectively, “COBRA”), and by the Company’s current group health
insurance policies, you will be eligible to continue your group health insurance benefits at your own expense thereafter, subject to Kosan’s commitment above, to cover your COBRA premiums (if elected) through November 2007. Within the timing
required by applicable law, you will be provided with a separate notice describing your rights and obligations under COBRA. 
 Stock Options

 During your employment, you have received options to purchase 150,000 shares of Kosan stock (the “Options”). Pursuant to the terms of the
Company’s 2006 Equity Incentive Plan (the “Plan”) and your grant agreement(s), if the parties enter into the Consulting Agreement, vesting of your Options will continue so long as there is no termination or interruption of your
“Continuous Service” (as defined in the Plan) to the Company. Once a termination or interruption of your Continuous Service occurs (which will be no later than the termination of the Consulting Agreement), then you will be entitled to
exercise your vested shares subject to the Options, if any, within ninety (90) days thereafter pursuant to the terms and conditions of the Plan and your option agreement(s). 
 Please note that the Options will be taxed as a nonstatutory stock option upon exercise. Accordingly, as a condition to exercise any vested shares subject to the Options, you will be responsible (and you agree to
reimburse the Company) for all applicable federal and state income and employment taxes that the Company is required to withhold as a result of such exercise, and no shares of the Company’s common stock will be issued to you in respect of your
exercise of the Options unless and until you satisfy such tax withholding obligations. You hereby acknowledge that the Company is not providing tax advice to you and that you have been advised by the Company to seek independent tax advice with
respect to the exercise of the Options and your receipt of the Severance Benefits. 
 Proprietary Obligations 
 You are reminded of your obligations under your Employee Proprietary Information and Inventions Agreement that you signed on October 25, 2006 (the “Proprietary
Information Agreement”). These obligations continue after the termination of your employment. A copy of your Proprietary Information Agreement is enclosed for your reference. 
  

 Page 3 of 3 
  

 Return of Company Property 
 It is extremely important that you promptly review all of your computer files and documents in your possession or control to ensure that you have no information, materials or documents of the Company or that concern the Company’s
business. You should also carefully review your home computer, if you have one, and all files that you keep at your home or elsewhere to identify any and all materials that contain any confidential or proprietary information of the Company. All such
materials or property in your possession must be returned to the Company immediately. Failure to comply will render you ineligible for the Severance Benefits. 
 This letter sets forth the complete understanding and agreement between you and the Company with regard to your employment transition, and it is entered into without reliance on any promise or representation, written or oral, other than
those expressly contained herein. This letter supersedes any other discussions or representations relating to your transition terms, and the terms set forth in this letter may not be changed except in a writing signed by both you and a duly
authorized officer of the Company. 
 If you have any questions or concerns regarding the Severance Benefits or any other contents of this letter, please
contact Mary Ann Rafferty. 
 Please acknowledge your receipt of this letter and the described enclosures, and your agreement to the above, by signing in the
space provided below. Both the enclosed Release Agreement and Consulting Agreement should not be signed until the Termination Date. 
 We wish you success in
your future endeavors. 
  

	
	 Best regards,
  
 KOSAN BIOSCIENCES INCORPORATED

	
	/s/ Robert G. Johnson
	 Robert G. Johnson, M.D., Ph.D.
 President and Chief
Executive Officer

  

	
	Acknowledged, Understood and Accepted:
	
	/s/ Robert De Jager M.D.
	Robert De Jager, M.D.
	
	8/1/2007
	Date

 Enclosures: 
  

	•	Release Agreement 

  

	•	Consulting Agreement 

  

	•	Employee Proprietary Information and Inventions Agreement 

 CONSULTING AGREEMENT 
 THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into by and between KOSAN BIOSCIENCES
INCORPORATED, a Delaware corporation having an address at 3832 Bay Center Place, Hayward, CA 94545 (the “Company”), and ROBERT DE JAGER, M.D., an individual, having an
address at [address], (“Consultant”), effective as of August 8, 2007 (the “Effective Date”). 
 RECITALS 
 WHEREAS, Consultant has skills and knowledge in the
Company’s field of endeavor and thus is well suited to advise the Company; and 
 WHEREAS, the
Company desires that Consultant advise and consult with the Company in Consultant’s area of expertise and on the terms and conditions set forth herein. 
 NOW THEREFORE, in consideration of the mutual obligations specified in this Agreement, the parties agree to the following: 
 1. CONSULTING SERVICES. Consultant shall provide consulting services to the Company, the specific nature and
amount of which shall be as described generally in Exhibit A and in accordance with the Company’s more specific instructions. Exhibit A lists Consultant’s main contact person for the Services, and this person will be the primary source of
Company’s more specific instructions regarding the Services. The Company may change Consultant’s main contact upon written notice. Consultant will perform the Services in strict accordance with Exhibit A and the Company’s other
directions, using Consultant’s highest degree of professional skill and expertise. 
 Consultant shall render the Services at such times
and in such quantities as are set forth in Exhibit A. Consultant shall perform the Services at the Company’s principal place of business, another Company location, or at other places set forth in Exhibit A. 
 2. COMPENSATION. Company shall compensate Consultant in accordance with Exhibit A for Services
actually provided by Consultant in accordance with this Agreement. 
 3. AMENDMENTS TO
EXHIBIT A. Exhibit A sets forth the specifics of the Services, the location of the Services and compensation for the Services as of the Effective Date. Exhibit A may only be amended by a writing signed by an authorized
representative of each party (in the case of the Company, a person having a seniority level of Senior Vice President or higher). 
 4.
INDEPENDENT CONTRACTOR STATUS. It is understood and agreed that Consultant is an independent contractor, is not an agent or employee of the Company, and is not
authorized to act on behalf of the Company. Consultant agrees not to hold Consultant out as, or give any person any reason to believe that Consultant is an employee, agent, joint venturer or partner of the Company. Consultant will not be eligible
for any employee benefits, nor will the 

  

 4 

 
Company make deductions from any amounts payable to Consultant for taxes or insurance (except to the extent the Company is required by law to do so). All
payroll and employment taxes, insurance, and benefits shall be the sole responsibility of Consultant. Consultant retains the right to provide services for others during the term of this Agreement and is not required to devote Consultant’s
services exclusively for the Company, provided that, during the term of this Agreement, Consultant may not provide services (as a consultant, employee, or in any other status) to a competing entity of the Company, or engage in activities that
compete with the Company or that otherwise conflict with his duties to the Company hereunder. 
 5. NO
SOLICITATION. During the term of this Agreement and for one (1) year after its termination, Consultant will not personally recruit, solicit or induce, or attempt to recruit, solicit or induce, any employee or independent
contractor of the Company to terminate his or her employment or contractor relationship, as applicable, with the Company. 
 6.
CONFIDENTIAL INFORMATION. 
 6.1 Company Information. During the term of this
Agreement and in the course of Consultant’s performance hereunder, Consultant may receive or otherwise be exposed to confidential or proprietary information relating to the Company’s technology know-how, data, inventions, developments,
plans, business practices or strategies. Such confidential or proprietary information of the Company (collectively referred to as “Information”) may include but not be limited to: (i) confidential or proprietary information supplied
to Consultant with the legend “Confidential” or equivalent; (ii) the Company’s marketing and customer support strategies, financial information (including sales, costs, profits and pricing methods), internal organization,
employee information, and customer lists; (iii) the Company’s technology, including, but not limited to, discoveries, inventions, research and development efforts, data, software, trade secrets, processes, samples, media and/or cell lines
(and procedures and formulations for producing any such samples, media and/or cell lines), vectors, viruses, assays, plasmids, formulas, methods, product and know-how and show-how; (iv) all derivatives, improvements, additions, modifications,
and enhancements to any of the above, including any such information or material created or developed by Consultant under this Agreement; or (v) information of third parties as to which the Company has an obligation of confidentiality.
Consultant agrees that any Information provided to Consultant prior to the Effective Date shall be considered “Information” and protected hereunder. 
 Consultant acknowledges the confidential and secret character of the Information and agrees that the Information (with the exception of information in category (v)) is the sole, exclusive and extremely valuable
property of the Company. Accordingly, Consultant shall not reproduce any of the Information without the applicable prior written consent of the Company, use the Information except in the performance of this Agreement, nor disclose all or any part of
the Information in any form to any third party, either during or after the term of this Agreement. Upon termination of this Agreement for any reason, including expiration of term, Consultant agrees to cease using and to return to the Company all
whole and partial copies of the Information. 
  

 5 

 Consultant shall not remove from the premises of Company or otherwise transfer to any third party any
materials to which Company provides Consultant access, unless Consultant has express advance written consent from Company. 
 6.2
Other Employer Information. Consultant agrees that Consultant will not, during Consultant’s engagement with the Company, improperly use or disclose any proprietary information or trade secrets of Consultant’s former or
concurrent employers or companies with which Consultant has or has had a consulting or other relationship, if any, and that Consultant will not bring onto the premises of the Company any unpublished documents or any property belonging to
Consultant’s former or concurrent employers or companies unless consented to in writing by said employers or companies. 
 6.3
Third Party Information. Consultant recognizes that the Company has received and in the future will receive from third parties their confidential or proprietary information subject to a duty on the Company’s part to maintain the
confidentiality of such information and, in some cases, to use it only for certain limited purposes. Consultant agrees that Consultant owes the Company and such third parties, both during the term of Consultant’s engagement and thereafter, a
duty to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation (except in a manner that is consistent with the Company’s agreement with the third party) or use
it for the benefit of anyone other than the Company or such third party (consistent with the Company’s agreement with the third party). 
 7. INVENTIONS. 
 7.1 Disclosure of Inventions.
Consultant shall promptly and fully disclose to the Company any and all ideas, improvements, inventions, know-how, techniques and works of authorship learned, conceived or developed by Consultant pursuant to Consultant’s performance of the
Services for the Company or pursuant to any services provided to the Company prior to the Effective Date (together with all intellectual property rights therein (including without limitation patent applications and patents), the “Consulting
Inventions”). Consultant shall keep and maintain adequate and current records (in the form of notes, sketches, drawings or in any other form that may be required by the Company) of all work performed relating to the Services, including all
proprietary information developed relating thereto. Such records shall be available to and remain the sole property of the Company at all times. 
 7.2 Inventions Assigned to the Company. Consultant agrees that any and all Consulting Inventions shall be the sole and exclusive property of the Company. Accordingly, Consultant hereby assigns to the Company all
Consultant’s right, title and interest in and to the Consulting Inventions, and agrees to execute and deliver all documents and take all reasonable, lawful actions to assist the Company to evidence or record such assignment or perfect or
enforce the Consulting Inventions. Further, if Company is unable, after making reasonable inquiry, to obtain Consultant’s signature on any such documents, Consultant hereby appoints Company as Consultant’s attorney-in-fact to execute and
deliver such documents. 
  

 6 

 7.3 Proprietary Information and Inventions of Concurrent Employers. The Company acknowledges
that Consultant may be concurrently employed by others during the course of this Agreement. The Company shall have no rights to the proprietary information or inventions developed by Consultant during the course of
his employment with such concurrent employers. 
 8. TERMINATION. Either party may terminate this Agreement
at any time by giving the other party thirty (30) days written notice. Either party may terminate this Agreement upon written notice in the case of material breach of the terms of this Agreement by the other party, if such breach remains
uncured thirty (30) days after written notice of such breach is sent by the terminating party. In the event of any termination, Consultant shall cease work immediately, unless otherwise advised by the Company, shall return to the Company all
Information, Consulting Inventions, and other materials belonging to the Company, and shall notify the Company of costs incurred up to the termination date. Sections 5, 6, 7, 8, 10, 11 and 12 of this Agreement shall survive any termination of this
Agreement. In the event that the Agreement is not terminated earlier as provided herein, it shall expire by its terms, and terminate, on November 8, 2007 unless the parties agree in writing to extend the term of the Agreement. 
 9. COMPLIANCE WITH APPLICABLE LAWS. Consultant
warrants that all material supplied and work performed under this Agreement complies with or will comply with all applicable United States and foreign laws and regulations. 
 10. ASSIGNMENT; BENEFIT. This Agreement is for the personal services of Consultant and
may not be assigned by Consultant. Consultant may not delegate any of Consultant’s duties under this Agreement nor shall it be assignable by Consultant by operation of law, without the prior written consent of the Company. This Agreement may be
assigned at any time by the Company in its discretion, provided that Consultant would not be required to perform personal services for any entity other than an entity (a) affiliated with the Company or (b) that has merged with or
acquired all or substantially all of the Company’s assets to which the Services relate. The parties’ rights and obligations under this Agreement will bind and inure to the benefit of their respective successors, heirs, executors, and
administrators and permitted assigns. 
 11. LEGAL AND EQUITABLE
REMEDIES. Consultant hereby acknowledges and agrees that if Consultant breaches this Agreement, including, without limitation, by the actual or threatened disclosure of Information or Consulting Inventions without the prior
express written consent of the Company, the Company will suffer an irreparable injury, such that no remedy at law will afford it adequate protection against, or appropriate compensation for, such injury. Accordingly, Consultant hereby agrees that
the Company shall be entitled to specific performance of Consultant’s obligations under this Agreement, as well as such further relief as may be granted by a court of competent jurisdiction. 
 12. GOVERNING LAW; SEVERABILITY. This Agreement shall be governed by and construed according
to the laws of California, without giving effect to its conflict of laws rules. If any provision of this Agreement is found by a court of competent jurisdiction to be unenforceable, that provision shall be severed and the remainder of this Agreement
shall 

  

 7 

 
continue in full force and effect. Any disputes arising under this Agreement shall be resolved by trial to a judge as the finder of fact seated in a court of
competent subject matter jurisdiction in San Mateo or San Francisco counties, California. Each party hereby consents to, and waives any defenses that party may have to or conflicting with, the personal jurisdiction and venue of all such courts or
relating to trial to a judge (including without limitation the defense of forum non conveniens). 
 13.
COMPLETE UNDERSTANDING; MODIFICATION. This Agreement constitutes the final, exclusive and complete understanding and agreement of the Company and Consultant with
respect to the subject matter hereof. There are no other understandings, agreements, representations or warranties between the parties with respect to that subject matter other than those set forth in this Agreement. Any waiver, modification or
amendment of any provision of this Agreement shall be effective only if in writing and signed by a Company officer. 
 14.
NOTICES. Any notices required or permitted hereunder shall be given to the appropriate party at the address specified below or at such other address as the party shall specify in writing. Such notice shall be deemed given upon
personal delivery to the appropriate address or sent by certified or registered mail, three days after the date of mailing. Either party may update its notice address by written notice to the other party. 
  

					
	If to the Company:	 		  	If to the Consultant:
			
	 Kosan Biosciences Incorporated
 3832 Bay Center Place

 Hayward, CA 94545
 Attention: General Counsel
	 		  	

 IN WITNESS WHEREOF, the parties hereto have
executed this Agreement as of the date first set forth above. 
  

					
	KOSAN BIOSCIENCES INCORPORATED	 		 	ROBERT DE JAGER, M.D.
			
	/s/ Robert G. Johnson, Jr.	 		 	/s/ Robert De Jager
	PRINTED NAME: Robert G. Johnson, Jr.	 		 	PRINT NAME: Robert De Jager, M.D.
	TITLE: President & CEO	 		 	SOCIAL SECURITY NUMBER:
                    

  

 8 

 EXHIBIT A 
 WORK PLAN, COMPENSATION 
 Work Plan:

 Consultant will provide general consulting services as requested from time to time. Consultant’s primary contact at the Company shall be Robert G.
Johnson, M.D., Ph.D., President and Chief Executive Officer. 
 Term of Service: 
 Until November 8, 2007 unless earlier terminated in accordance with this Agreement, or extended by mutual written agreement of Consultant and an officer of the Company. 
 Compensation: 
 Consultant shall be paid $250 per hour actually spent
performing the Services (excluding de minimis Services), not to exceed ten (10) hours per month without the Company’s prior written approval. Payments will be processed within thirty (30) days after receipt by Company of
Consultant’s itemized invoice therefor (which invoice shall contain a written description of the day(s) that Consultant provided services, the amount of time, and a description of the provided services with respect to all time invoiced).

 Stock Option Awards: 
 Consultant and the Company agree
to the following regarding the stock option grants (the “Options”) provided to Consultant in connection with Consultant’s former employment with the Company: 
 To the maximum extent consistent with the Company’s 2006 Equity Incentive Plan (the “Plan”) and Consultant’s grant agreement(s), Consultant’s service to the Company under the Consulting
Agreement shall constitute “Continuous Service” (as defined in the Plan) and vesting of the Options will continue so long as there is no termination or interruption of Consultant’s Continuous Service. Once a termination or
interruption of Consultant’s Continuous Service occurs (which will be no later than the termination of the Consulting Agreement), then Consultant will be entitled to exercise any vested shares subject to the Options within ninety (90) days
thereafter pursuant to the terms and conditions of the Plan and Consultant’s option agreement(s).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}]]